>
Switch to:

ZIOPHARM Oncology Financial Strength

: 5 (As of Sep. 2020)
View and export this data going back to 2005. Start your Free Trial

ZIOPHARM Oncology has the Financial Strength Rank of 5.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate ZIOPHARM Oncology's interest coverage with the available data. As of today, ZIOPHARM Oncology's Altman Z-Score is 0.00.


Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


ZIOPHARM Oncology Financial Strength Distribution

* The bar in red indicates where ZIOPHARM Oncology's Financial Strength falls into.



ZIOPHARM Oncology Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

ZIOPHARM Oncology's Interest Expense for the months ended in Sep. 2020 was $0.00 Mil. Its Operating Income for the months ended in Sep. 2020 was $-20.32 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2020 was $1.66 Mil.

ZIOPHARM Oncology's Interest Coverage for the quarter that ended in Sep. 2020 is

GuruFocus does not calculate ZIOPHARM Oncology's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies interest coverage is at least 5. ZIOPHARM Oncology Inc has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

ZIOPHARM Oncology's Debt to Revenue Ratio for the quarter that ended in Sep. 2020 is

Debt to Revenue Ratio=Total Debt (Q: Sep. 2020 ) / Revenue (Q: Sep. 2020 )
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.866 + 1.655) / 0
=

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

ZIOPHARM Oncology has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


ZIOPHARM Oncology  (NAS:ZIOP) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

ZIOPHARM Oncology has the Financial Strength Rank of 5.


ZIOPHARM Oncology Financial Strength Related Terms


ZIOPHARM Oncology Financial Strength Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)